Download PDF
Semin Neurol 2015; 35(06): 683-689
DOI: 10.1055/s-0035-1564303
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuromuscular Emergencies

Robert Bucelli
1   Neuromuscular Division, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
,
Matthew B. Harms
1   Neuromuscular Division, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
› Author Affiliations
Further Information

Publication History

Publication Date:
23 November 2015 (online)

    Permissions and Reprints

Abstract

Although most neuromuscular disorders are recognized and treated in the outpatient clinic, a subset can present with rapidly advancing or severe weakness and constitute true emergencies by threatening respiratory and bulbar function. This review focuses on the recognition, diagnosis, and management of neuromuscular diseases most likely to present in the inpatient setting: infectious motor neuronopathies, inflammatory polyradiculopathies, and disorders of neuromuscular transmission. In each, the prompt recognition, diagnosis, and institution of specific therapies or supportive care can prevent mortality and mitigate morbidity.

Keywords

neuromuscular - motor neuronopathy - Guillain-Barré syndrome - myasthenia gravis
 

  • References

  • 1 Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. JAMA 2013; 310 (3) 308-315
    CrossrefPubMedGoogle Scholar
  • 2 Greninger AL, Naccache SN, Messacar K , et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 2015; 15 (6) 671-682
    CrossrefPubMedGoogle Scholar
  • 3 Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341 (13) 936-942
    CrossrefPubMedGoogle Scholar
  • 4 Cumings JN. The cerebrospinal fluid in poliomyelitis. Postgrad Med J 1949; 25 (279) 19
    CrossrefPubMedGoogle Scholar
  • 5 Maiti B, Bucelli RC. Atypical CSF findings in West Nile neuroinvasive disease: a diagnostic and therapeutic conundrum. Neurol Neuroimmunol Neuroinflamm 2014; 1 (1) e8
    PubMedGoogle Scholar
  • 6 Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology 2006; 66 (3) 361-365
    CrossrefPubMedGoogle Scholar
  • 7 Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol 2005; 26 (8) 1986-1995
    PubMedGoogle Scholar
  • 8 Lindsey NP, Staples JE, Lehman JA, Fischer M ; Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease - United States, 1999–2008. MMWR Surveill Summ 2010; 59 (2) 1-17
    PubMedGoogle Scholar
  • 9 Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007; 370 (9603) 1947-1959
    CrossrefPubMedGoogle Scholar
  • 10 Centers for Disease Control and Prevention (CDC). Tetanus surveillance --- United States, 2001–2008. MMWR Morb Mortal Wkly Rep 2011; 60 (12) 365-369
    PubMedGoogle Scholar
  • 11 Centers for Disease Control (CDC). Tetanus—United States, 1987 and 1988. MMWR Morb Mortal Wkly Rep 1990; 39 (3) 37-41
    PubMedGoogle Scholar
  • 12 Brook I. Current concepts in the management of Clostridium tetani infection. Expert Rev Anti Infect Ther 2008; 6 (3) 327-336
    CrossrefPubMedGoogle Scholar
  • 13 LaForce FM, Young LS, Bennett JV. Tetanus in the United States (1965-1966):epidemiologic and clinical features. N Engl J Med 1969; 280 (11) 569-574
    CrossrefPubMedGoogle Scholar
  • 14 Bunch TJ, Thalji MK, Pellikka PA, Aksamit TR. Respiratory failure in tetanus: case report and review of a 25-year experience. Chest 2002; 122 (4) 1488-1492
    CrossrefPubMedGoogle Scholar
  • 15 Ganesh Kumar AV, Kothari VM, Krishnan A, Karnad DR. Benzathine penicillin, metronidazole and benzyl penicillin in the treatment of tetanus: a randomized, controlled trial. Ann Trop Med Parasitol 2004; 98 (1) 59-63
    CrossrefPubMedGoogle Scholar
  • 16 Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed) 1985; 291 (6496) 648-650
    CrossrefPubMedGoogle Scholar
  • 17 Frenzen PD. Hospital admissions for Guillain-Barré syndrome in the United States, 1993-2004. Neuroepidemiology 2007; 29 (1-2) 83-88
    CrossrefPubMedGoogle Scholar
  • 18 Hadden RD, Cornblath DR, Hughes RA , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (5) 780-788
    CrossrefPubMedGoogle Scholar
  • 19 Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64 (1) 74-77
    CrossrefPubMedGoogle Scholar
  • 20 Guillain-Barre Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci 2000; 21 (4) 229-234
    CrossrefPubMedGoogle Scholar
  • 21 Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008; 70 (18) 1608-1613
    CrossrefPubMedGoogle Scholar
  • 22 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; 7: CD001798
    PubMedGoogle Scholar
  • 23 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 9: CD002063
    PubMedGoogle Scholar
  • 24 Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve 2001; 24 (7) 963-965
    CrossrefPubMedGoogle Scholar
  • 25 Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72 (18) 1548-1554
    CrossrefPubMedGoogle Scholar
  • 26 Ramos-Fransi A, Rojas-García R, Segovia S , et al; Myasthenia NMD-ES Study Group. Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 2015; 22 (7) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 27 Sakaguchi H, Yamashita S, Hirano T , et al. Myasthenic crisis patients who require intensive care unit management. Muscle Nerve 2012; 46 (3) 440-442
    CrossrefPubMedGoogle Scholar
  • 28 Witoonpanich R, Dejthevaporn C, Sriphrapradang A, Pulkes T. Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin Neurophysiol 2011; 122 (9) 1873-1877
    CrossrefPubMedGoogle Scholar
  • 29 Vincent A, Leite MI, Farrugia ME , et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008; 1132: 84-92
    CrossrefPubMedGoogle Scholar
  • 30 Díaz-Manera J, Martínez-Hernández E, Querol L , et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78 (3) 189-193
    CrossrefPubMedGoogle Scholar
  • 31 Nikolic A, Djukic P, Basta I , et al. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clin Neurol Neurosurg 2013; 115 (4) 432-437
    CrossrefPubMedGoogle Scholar
  • 32 Thomas CE, Mayer SA, Gungor Y , et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48 (5) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 33 Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76 (23) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 34 Kull S, Schulz KM, Weisemann J , et al. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS ONE 2015; 10 (2) e0116381
    CrossrefPubMedGoogle Scholar
  • 35 Brown N, Desai S. Infantile botulism: a case report and review. J Emerg Med 2013; 45 (6) 842-845
    CrossrefPubMedGoogle Scholar
  • 36 Souayah N, Mehyar LS, Khan HM , et al. Trends in outcome and hospitalization charges of adult patients admitted with botulism in the United States. Neuroepidemiology 2012; 38 (4) 233-236
    CrossrefPubMedGoogle Scholar
  • 37 Mann JM, Martin S, Hoffman R, Marrazzo S. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981; 71 (3) 266-269
    CrossrefPubMedGoogle Scholar